参考文献[2]
NiuK, HozawaA, KuriyamaS, et al. Dietary long- chain n-3 fatty acids of marine origin and serum C- reactive protein concentrations are associated in a population with a diet rich in marine products [J]. Am J Clin Nutr, 2006, 84(1): 223–229.
[3]
SunS, WuH, ZhangQ, et al. Subnormal peripheral blood leukocyte counts are related to the lowest prevalence and incidence of metabolic syndrome: Tianjin chronic low-grade systemic inflammation and health cohort study [J]. Mediators Inflamm, 2014:412386. .
[4]
NiuK, HozawaA, GuoH, et al. C- reactive protein (CRP) is a predictor of high medical- care expenditures in a community- based elderly population aged 70 years and over: the Tsurugaya project [J]. Arch Gerontol Geriatr, 2012, 54(3): e392–397.
[5]
NiuK, HozawaA, GuoH, et al. Serum C-reactive protein even at very low (<1.0 mg/l) concentration is associated with physical performance in a community-based elderly population aged 70 years and over [J]. Gerontology, 2008, 54(5):260–267.
[6]
NiuK, KobayashiY, GuanL, et al. Low-fat dairy, but not whole-/high-fat dairy, consumption is related with higher serum adiponectin levels in apparently healthy adults [J]. Eur J Nutr, 2013, 52(2):771–778.
[7]
KobayashiY, NiuK, GuanL, et al. Oral health behavior and metabolic syndrome and its components in adults [J]. J Dent Res, 2012, 91(5):479–484.
[8]
BuckleyDI, FuR, FreemanM, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force [J]. Ann Intern Med, 2009, 151(7):483–495.
[9]
BhatT, TeliS, RijalJ, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review [J]. Expert Rev Cardiovasc Ther, 2013, 11(1): 55–59.
[10]
EnsrudK, GrimmRH. The white blood cell count and risk for coronary heart disease [J]. Am Heart J, 1992, 124(1):207–213.
[11]
LeeCD, FolsomAR, NietoFJ, et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study [J]. Am J Epidemiol, 2001, 154(8):758–764.
[12]
KandaT, TakahashiT. Interleukin-6 and cardiovascular diseases [J]. Jpn Heart J, 2004, 45(2):183–193.
[13]
CastellJV, Gomez-LechonMJ, DavidM, et al. Recombinant human interleukin- 6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes [J]. FEBS Lett, 1988, 232(2):347–350.
[14]
WilsonAM, RyanMC, BoyleAJ. The novel role of C- reactive protein in cardiovascular disease: risk marker or pathogen [J]. Int J Cardiol, 2006, 106(3): 291–297.
[15]
SciricaBM, MorrowDA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out [J]. Circulation, 2006, 113(17): 2128–2134, .
[16]
VermaS, DevarajS, JialalI. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis [J]. Circulation, 2006, 113(17): 2135–2150, .
[17]
GrivennikovSI, KarinM. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage [J]. Ann Rheum Dis, 2011, 70 (Suppl 1):i104–108.
[18]
KulbeH, ThompsonR, WilsonJL, et al. The inflammatory cytokine tumor necrosis factor- alpha generates an autocrine tumor- promoting network in epithelial ovarian cancer cells [J]. Cancer Res, 2007, 67(2):585–592.
[19]
AzadN, RojanasakulY, VallyathanV. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species [J]. J Toxicol Environ Health B Crit Rev, 2008, 11(1):1–15.
[20]
ShoelsonSE, LeeJ, GoldfineAB. Inflammation and insulin resistance [J]. J Clin Invest, 2006, 116(7):1793–1801.
[21]
AndersenK, PedersenBK. The role of inflammation in vascular insulin resistance with focus on IL- 6 [J]. Horm Metab Res, 2008, 40(9):635–639.
[22]
TackCJ, StienstraR, JoostenLA, et al. Inflammation links excess fat to insulin resistance: the role of the interleukin- 1 family [J]. Immunol Rev, 2012, 249(1):239–252.
[23]
DeBoerMD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions [J]. Nutrition, 2013, 29(2):379–386.
[24]
AggarwalBB, GehlotP. Inflammation and cancer: how friendly is the relationship for cancer patients? [J]. Curr Opin Pharmacol, 2009, 9(4):351–369.
[25]
PinatoDJ, StavrakaC, FlynnMJ, et al. An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials [J]. PLoS One, 2014, 9(1):e83279.
[26]
PradhanAD, MansonJE, RifaiN, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus [J]. JAMA, 2001, 286(3):327–334.
[27]
SprangerJ, KrokeA, MohligM, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population- based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study [J]. Diabetes, 2003, 52(3):812–817.
[28]
TsurudaT, KatoJ, SumiT, et al. Combined use of brain natriuretic peptide and C- reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus [J]. Vasc Health Risk Manag, 2007, 3(4):417–423.
[29]
RifaiN. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome [J]. Clin Chem, 2005, 51(3): 504–505.
[30]
de FerrantiS, RifaiN. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions [J]. Clin Chim Acta, 2002, 317(1-2):1–15.
[31]
RidkerPM, WilsonPW, GrundySM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? [J]. Circulation, 2004, 109(23): 2818–2825.
[32]
RidkerPM, RifaiN, RoseL, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events [J]. N Engl J Med, 2002, 347(20): 1557–1565.
[33]
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), WensleyF, GaoP, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data [J]. BMJ, 2011, 342: d548.
[34]
BlahaMJ, BudoffMJ, DeFilippisAP, et al. Associations between C- reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study [J]. Lancet, 2011, 378(9792):684–692.
[35]
SongK, DuH, ZhangQ, et al. Serum immunoglobulin M concentration is positively related to metabolic syndrome in an adult population: Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) Cohort Study [J]. PLoS One, 2014, 9(2):e88701.
[36]
ShiH, GuoX, ZhangQ, et al. Serum immunoglobulin M concentration varies with triglyceride levels in an adult population: Tianjin chronic low-grade systemic inflammation and health (TCLSIHealth) cohort study [J]. PloS One, 2015, 10(4):e0124255.
[37]
LiuX, ZhangQ, WuH, et al. Blood neutrophil to lymphocyte ratio as a predictor of hypertension [J]. 2015, pii: hpv034. .
[38]
JiaQ, LiC, XiaY, et al. Association between complement C3 and prevalence of fatty liver disease in an adult population: a cross-sectional study from the Tianjin chronic low-grade systemic inflammation and health (TCLSIHealth) cohort study [J]. PloS One, 2015, 10(4):e0122026.
[39]
BaoX, XiaY, ZhangQ, et al. Elevated serum complement C3 levels are related to development of prediabetes in an adult population: Tianjin chronic low-grade systematic inflammation and health (TCLSIHealth) cohort study [J]. Diabetic Medicine, 2015 ().
[40]
MathurN, PedersenBK. Exercise as a mean to control low-grade systemic inflammation [J]. Mediators Inflamm, 2008: 109502. . .
[41]
MykkänenOT, HuotariA, HerzigKH, et al. Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet [J]. PLoS One, 2014, 9(12):e114790.
[42]
MonkJM, TurkHF, LiddleDM, et al. n-3 polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity- associated breast cancer [J]. Nutrients, 2014, 6(11):4760–4793.
[43]
WoodAD, StrachanAA, ThiesF, et al. Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular risk [J]. Br J Nutr, 2014, 112(8): 1341–1352.
[44]
YanbaevaDG, DentenerMA, CreutzbergEC, et al. Systemic effects of smoking [J]. Chest, 2007, 131(5): 1557–1566.
[45]
VolpatoS, PahorM, FerrucciL, et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor- 1 in well- functioning older adults: the Health, Aging, and Body Composition study [J]. Circulation, 2004, 109(5):607–612.
[46]
GaoXR, AdhikariCM, PengLY, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome [J]. J Pharm Pharmacol, 2009, 61(11):1505–1510.
[47]
BavryAA, ThomasF, AllisonM, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative [J]. Circ Cardiovasc Qual Outcomes, 2014, 7(4):603–610.
[48]
IkedaY, ShimadaK, TeramotoT, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial [J]. JAMA, 2014, 312(23): 2510–2520.
[49]
RidkerPM, ThurenT, ZalewskiA, et al. Interleukin-1 beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) [J]. Am Heart J, 2011, 162(4):597–605.
[50]
EverettBM, PradhanAD, SolomonDH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis [J]. Am Heart J, 2013, 166(2):199–207e115.